Is the sharp, acute leg pain in a patient with restless‑leg syndrome caused by severe sleep deprivation rather than the syndrome itself?

Sharp, Acute Leg Pain in RLS: Not a Primary Symptom

Sharp, acute pain is not a typical manifestation of restless legs syndrome itself; when present in an RLS patient, it more likely reflects either severe sleep deprivation-induced hyperalgesia, a painful RLS subtype (characterized by burning rather than sharp sensations), or a separate pain condition.

Understanding RLS Sensory Characteristics

The classic sensory experience in RLS consists of:

• An overwhelming urge to move the limbs, often accompanied by unpleasant sensations described as achiness, tingling, or crawling 1
• When pain is present in RLS, it typically manifests as a burning sensation rather than sharp, acute pain 2
• In a large clinical series, 55-61% of RLS patients reported painful sensations, with "burning" being the most frequent sensory descriptor (37-44% of painful RLS cases) 2
• Painful RLS represents a severe subtype associated with greater sleepiness, fatigue, and higher treatment needs 2

Sleep Deprivation as a Pain Amplifier

Sleep disruption in RLS patients demonstrably lowers pain thresholds and amplifies pain processing, which could explain sharp pain complaints:

• Both treated and untreated RLS patients show reduced pain thresholds compared to controls, and mediation analyses confirm this reduction is attributable to sleep disturbance 3
• Sleep deprivation specifically increases pain sensitivity following acute muscle soreness, with one night of sleep withdrawal causing significantly larger reductions in pressure pain thresholds 4
• RLS patients demonstrate enhanced temporal summation of heat pain, reflecting aberrant central nervous system facilitation of pain transmission that persists even independent of sleep disturbance 3
• The overlapping mechanisms between RLS and pain disorders involve sleep fragmentation inducing increased inflammatory markers and reduced pain thresholds 5

Clinical Approach to Sharp Pain in RLS Patients

Immediate Assessment Priorities

• Distinguish RLS sensations from neuropathic or musculoskeletal pain: Sharp, lancinating pain suggests peripheral neuropathy (present in 21.5% of RLS patients) or a separate pain condition rather than RLS itself 1
• Quantify sleep disruption: Severe sleep deprivation can lower pain thresholds enough to make previously tolerable sensations feel acutely painful 3, 4
• Check iron status: Measure serum ferritin and transferrin saturation, as iron deficiency (ferritin ≤100 ng/mL or transferrin saturation <20%) worsens RLS and may indirectly worsen pain sensitivity 6

Treatment Algorithm

First-line therapy addresses both RLS and pain amplification:

1. Initiate gabapentinoids immediately regardless of iron status 7, 6:

   • Gabapentin: 300 mg at bedtime, titrate to 1800-2400 mg daily in divided doses 6
   • Gabapentin enacarbil: 600 mg once daily at 5 PM 6
   • Pregabalin: 75 mg at bedtime, titrate to 150-450 mg daily 6
   • These agents treat both RLS and neuropathic pain, with approximately 70% of patients showing much or very much improved symptoms versus 40% with placebo 1

2. Replete iron stores when indicated 6:

   • IV ferric carboxymaltose 1000 mg is preferred for rapid restoration without gastrointestinal side effects (strong recommendation) 7, 6
   • Oral ferrous sulfate 325-650 mg daily or every other day is acceptable when IV access unavailable 6
   • Improvement typically occurs within weeks for IV iron, 4-12 weeks for oral 6

3. Discontinue exacerbating medications 6, 1:

   • Stop serotonergic antidepressants (SSRIs, SNRIs), dopamine antagonists (metoclopramide, prochlorperazine), and centrally acting antihistamines (diphenhydramine, hydroxyzine) 6

4. For refractory cases with persistent pain, consider low-dose opioids (methadone 5-10 mg daily) after gabapentinoid optimization 1

Common Pitfalls

• Do not assume all leg pain in RLS patients is RLS: Sharp, acute pain warrants evaluation for neuropathy, radiculopathy, or vascular disease 2
• Avoid dopamine agonists (pramipexole, ropinirole, rotigotine) as first-line therapy due to 7-10% annual augmentation risk, which causes iatrogenic worsening of symptoms 7, 6, 1
• Recognize that even treated RLS patients have elevated pain sensitivity: Pharmacologically managed RLS patients still demonstrate reduced pain thresholds compared to controls, placing them at long-term risk for persistent pain conditions 3